School of Medicine


Showing 1-2 of 2 Results

  • Richard Fan

    Richard Fan

    Engineering Res Assoc, Urology - Divisions

    Bio Richard E. Fan, Ph.D., is an Engineering Research Associate of Urology at Stanford University.

    Dr. Fan’s research relates to the development of clinically driven biomedical instrumentation and medical devices. He is interested in translational application of emerging technologies in the medical and surgical spaces, as well as the development of platforms to explore clinical and pre-clinical evaluation. His primary work is currently focused on image guided detection and treatment of prostate cancer, including MR-US fusion, focal therapies, embedded systems and robotics.

    Dr. Fan was an Associate Research Scientist of Urology and Lecturer of Mechanical Engineering at Yale University before moving to Stanford. While at Yale, he served as a Co-Founder and the inaugural Engineering Director of the Yale Center for Biomedical and Interventional Technology (CBIT), an interdisciplinary center focused on catalyzing greater medical device innovation on campus. He also co-developed pilot curriculum in the department of Mechanical Engineering with MENG 404: Medical Device Design and Innovation, an undergraduate design experience focusing on bridging the gap between engineering and medicine.

  • Catherine A. Gordon

    Catherine A. Gordon

    Postdoctoral Research fellow, Urology

    Current Research and Scholarly Interests Prostate cancer is a major health problem in the United States. The American Cancer Society estimates that one out of six men will be diagnosed with prostate cancer during his lifetime, while one out of thirty-six men will die from it. Since most men will not acquire an aggressive and potentially lethal form of the disease, the challenge is being able to distinguish between aggressive and indolent forms of prostate cancer, and properly treating the aggressive forms.

    We have recently identified nucleolar and spindle-associated protein (NUSAP1; encoding NuSAP) as a prognosticator for prostate cancer. We found that NUSAP1 is over-expressed in recurrent prostate cancer tumors, and validated this correlation in independent prostate cancer datasets. Although NuSAP is known to be essential for cell cycle progression, faithfully binding to and stabilizing microtubules during mitosis, little is known about its role in prostate cancer progression. Hence, we are performing an extensive analysis to understand the role of NuSAP in aggressive prostate cancer. In particular, we are investigating the regulation and role of NuSAP in mechanisms of proliferation, invasion, apoptosis, cellular movement, cell cycle progression, metastasis, tumor growth, and responses to chemotherapy. Understanding the role of NuSAP in prostate cancer progression will provide insights into the inner workings of aggressive cancer cells, and may lead to new ways to prognosticate and treat aggressive forms of prostate cancer.

Stanford Medicine Resources: